Table 2.
Patient characteristics - advanced gastroenteropancreatic neuroendocrine tumours with and without carcinoid syndrome n (%)
| All patients n = 50 | With carcinoid syndrome n = 25 | Without carcinoid syndrome n = 25 | P value | |
| Age (median) | 65.5 | 67 | 62 | 0.19 |
| 95%CI | (61.5-68.5) | (61.3-70.9) | (58.0-68.9) | |
| Gender | F:21 (42) M:29 (58) | F:9 (36) M:16 (64) | F: 12 (48) M: 13 (52) | 0.39 |
| Median time since diagnosis (mo) | 39 | 45 | 36 | 0.66 |
| (95%CI) | (21.54-48.46) | (20.10-48.90) | (18.21-56) | |
| Prior Surgery | 24 (48) | 9 (36) | 15 (60) | 0.09 |
| Recurrent disease following previous curative intent treatment | 8 (16) | 3 (12) | 5 (20) | 0.44 |
| Primary disease site | ||||
| Stomach | 1 (2) | 0 (0) | 1 (4) | |
| Small bowel | 29 (58) | 18 (72) | 11 (44) | |
| Pancreas | 11 (22) | 1 (4) | 10 (40) | |
| Large bowel | 3 (6) | 1 (4) | 2 (8) | |
| Unknown GI tract | 6 (12) | 5 (20) | 1 (4) | |
| Median Ki-67 | ||||
| % (95%CI) | 3 (2-4.8) | 2 (2-5) | 3 (2-7.7) | 0.55 |
| ECOG PS n (%) | ||||
| 0 | 14 (27) | 7 (28) | 7 (28) | |
| 1 | 30 (60) | 16 (64) | 14 (56) | |
| 2 | 4 (8) | 1 (4) | 3 (12) | |
| 3 | 2 (4) | 1 (4) | 1 (4) | |
| Current treatment | ||||
| Nil | 5 (10) | 2 (8) | 4 (16) | |
| Best supportive care | 1 (2) | 0 (0) | 1 (4) | |
| Chemotherapy | 5 (10) | 0 (0) | 5 (20) | |
| Interferon + Somatostatin analogue | 2 (4) | 2 (8) | 0 (0) | |
| Peptide receptor radionuclide Therapy | 2 (4) | 1 (4) | 1 (4) | |
| Peptide receptor radionuclide therapy + Somatostatin analogues | 2 (4) | 1 (4) | 1 (4) | |
| Somatostatin analogues | 28 (56) | 8 (72) | 9 (36) | |
| Tryptophan hydroxylase inhibitor + Somatostatin analogues | 1 (2) | 1 (4) | 0 (0) | |
| mTOR inhibitor | 4 (8) | 0 (0) | 4 (16) | |
| Use of psychoactive medications | ||||
| Nil | 44 (88) | 22 (88) | 22 (88) | |
| Selective serotonin Reuptake inhibitors | 3 (6) | 1 (4) | 2 (8) | |
| Benzodiazepine | 1 (2) | 1 (4) | 0 (0) | |
| Selective serotonin reuptake inhibitors + benzodiazepine | 1 (2) | 0 (0) | 1 (4) | |
| Unknown | 1 (2) | 1 (4) | 0 (0) | |
CI: Confidence interval; ECOG PS: Eastern Cooperative Oncology Group performance status.